Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Acalabrutinib in Relapsed/Refractory Mantle Cell Lymphoma
2014-002117-28Phase 2Unknown
- Sponsor
- Acerta Pharma
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Primary endpoint: Overall response rate. Status: unknown.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2014-002117-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002117-28.